Navigation Links
Medivation's Dimebon Maintains Statistically Significant Benefit on,All Five Efficacy Endpoints in Alzheimer's Disease Trial After One,Year of Therapy

- Aggregate Benefit over Placebo Larger at One Year than at Six Months -

SAN FRANCISCO and WASHINGTON, June 11, 2007 /PRNewswire-FirstCall/ -- Medivation, Inc. today announced that the benefits of Dimebon over placebo in its double-blind, placebo-controlled Phase 2 study in mild-to- moderate Alzheimer's disease were statistically significant on all five study endpoints at 12 months. Importantly, on every endpoint studied, the benefits of Dimebon over placebo at one year were stable or greater when compared to benefits at six months. Dimebon patients were stabilized over the one year study period, meaning that their level of function was preserved for a full year on all five endpoints. The endpoints spanned all of the most frequently studied aspects of Alzheimer's disease: cognition, overall clinical function, activities of daily living, and behavioral problems. Dimebon was well tolerated throughout the entire one-year treatment period.

On the study's primary endpoint, the ADAS-cog, Dimebon caused an improvement over placebo of 6.9 points at one year (observed case analysis; p<0.0001). On the global function endpoint used in this study, the CIBIC- plus, Dimebon's benefit over placebo was 0.8 points at 12 months (observed case analysis; p=0.006). Global function improved or remained stable in 69 percent of treated Alzheimer's disease patients after one year of Dimebon therapy. The ADAS-cog and the CIBIC-plus are the two endpoints the U.S. Food and Drug Administration has used to approve all currently marketed drugs for mild-to-moderate Alzheimer's disease.

Dimebon produced an aggregate benefit over placebo in this study that was larger at 12 months than at six. After a year of treatment Dimebon's benefit over placebo was greater than six-month levels on the ADAS-cog (6.9 points vs. 4.0 points), the CIBIC-plus (0.8 points vs. 0.6 points), and the ADCS-ADL (5.2 points vs. 2.9 points); however, only th
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Medivation to Host Conference Call to Discuss Top-Line 12-Month Results From Dimebon Alzheimers Disease Study
2. Medivation Announces Presentation of New Subset Analyses From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
3. Medivation Announces First U.S. Presentation of Data From Dimebon Phase 2 Alzheimers Disease Trial at American Academy of Neurology Annual Meeting
4. Medivation Announces Presentation of Full Top-Line Data From Dimebon Six-Month Trial at Major International Alzheimers Disease Conference
5. Neurologix Announces Publication of Landmark Gene Therapy Study Demonstrating Safety and Statistically Significant Improvement in Patients With Advanced Parkinsons Disease
6. Repros Androxal Shows Highly Statistically Significant Positive Effects in Men with Secondary Hypogonadism
7. ISTA Pharmaceuticals Announces Statistically Significant Preliminary Results From its U.S. Phase II/III Clinical Study Of Bepotastine
8. EPIX Pharmaceuticals Announces Statistically Significant Results in Cognitive Function from Phase 1b Clinical Trial of Novel 5-HT6 Drug Candidate
9. Telik Reports Positive Data Demonstrating Synergy in Combination and Highly Statistically Significant Effect of Telcyta as Maintenance Therapy in First-Line Non-Small Cell Lung Cancer
10. Addex Achieves Statistically Significant Outcome in Phase IIa Clinical Trial With ADX10059 in Gastro-Esophageal Reflux Disease
11. Repros Proellex Shows Statistically Significant Improvement in Primary Endpoint in Phase 2 Trial in the Treatment of Uterine Fibroids
Post Your Comments:
(Date:1/15/2014)...  According to Millennium Research Group (MRG), the global ... the United States and European transcatheter ... moderately through 2022, with embolization particles representing one ... in drug-eluting beads (DEBs) and radioembolization spheres in ...
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/14/2014)... InformEx, North America,s leading business ... hold the 30 th edition of its annual conference ... from January 21-24. (Logo: http://photos.prnewswire.com/prnh/20131028/NY05330LOGO-a ) ... chemical and specialty chemical companies will take part in the ...
Breaking Medicine Technology:US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 2US and European Transcatheter Embolization and Occlusion Device Market to Surpass $1.6 Billion by 2022 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Media Advisory: InformEx 2014 Events & Speaker Lineup for 30th Edition Conference in Miami Beach 2
(Date:4/17/2014)... the April issue of Immunity , Kevin J. ... Research, says it,s time to take a fresh look ... sepsis, which kills millions worldwide every year, including more ... into the bloodstream to fight an injury or infection ... maintaining good health without inflammation, wounds and infections ...
(Date:4/17/2014)... A Northwestern University synthetic biology team has created ... create programmable therapeutics that could travel the body ... disease. , Engineering cell-based, biological devices that monitor ... in clinical synthetic biology. However, no existing technology ... a patient,s physiological state and respond in a ...
(Date:4/17/2014)... Il. (April 17, 2014) Doctors who treat ... called lymphangioleiomyomatosis (LAM) can face an agonizing treatment ... of the disease and help relieve shortness of ... transplants, and sirolimus can cause potentially fatal complications ... pulmonologist Dr. Daniel Dilling, medical director of Loyola ...
(Date:4/17/2014)... NEW YORK, NY (April 16, 2014) The cause ... but a new study proposes that neurons may be ... own immune system, similar to the way autoimmune diseases ... attack the body,s cells. The study was published April ... is a new, and likely controversial, idea in Parkinson,s ...
(Date:4/17/2014)... 2014 By discovering a new mechanism that allows ... researchers at UC Irvine and the Salk Institute have ... or prevent stroke-induced brain damage. , A complex and ... death and primary reason for disability in the U.S. ... and lets blood-borne material into the brain, causing the ...
Breaking Medicine News(10 mins):Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Building 'smart' cell-based therapies 2Health News:Patients with rare lung disease face agonizing treatment dilemma 2Health News:Patients with rare lung disease face agonizing treatment dilemma 3Health News:Is Parkinson's an autoimmune disease? 2Health News:Study IDs new cause of brain bleeding immediately after stroke 2
... new study led by Fox Chase Cancer Center radiation ... scores determined by pathologists at Fox Chase Cancer Center ... scores from referring institutions. She presented the new ... Society for Radiation Oncology on Monday, October 3. ...
... busy," and "too complicated." These are the typical excuses ... they fail to use online error-reporting systems designed to ... Johns Hopkins investigators found instead that the most common ... trouble and embarrassment. Investigators e-mailed an anonymous survey ...
... the parents of women with polycystic ovary syndrome (PCOS) are more ... a hormonal disorder affecting about 10% of women of reproductive age. ... women and a leading cause of infertility. The study shows ... form of cardiovascular disease, and almost twice as likely to have ...
... severe 2009 H1N1 influenza who developed respiratory failure and were ... blood had a lower rate of in-hospital death than similar ... study appearing in JAMA . The study is being ... European Society of Intensive Care Medicine meeting in Berlin. ...
... HealthDay Reporter , TUESDAY, Oct. 4 (HealthDay News) -- ... fare just as well if they are released the same day ... new research shows. "[Discharging patients the same day] wasn,t ... Rao, lead author of a study appearing in the Oct. 5 ...
... News) -- ,Raw sewage contains thousands of undiscovered viruses, ... study suggests. Viruses are everywhere, but only about ... this study, researchers looked for the genetic signatures of ... and Africa. They detected the signatures of 234 known ...
Cached Medicine News:Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 2Health News:Fox Chase Gleason scores better predict prostate cancer's recurrence after radiation 3Health News:Survey reveals reasons doctors avoid online error-reporting tools 2Health News:Oxygenating system associated with lower risk of death for H1N1 patients with respiratory failure 2Health News:Oxygenating system associated with lower risk of death for H1N1 patients with respiratory failure 3Health News:Overnight Stay May Not Be Necessary for Stenting: Study 2Health News:Overnight Stay May Not Be Necessary for Stenting: Study 3Health News:Raw Sewage a New Frontier for Scientists 2
PRINCIPLE: The QC-SLIDES™ are specifically designed microscope slides intended to be part of the quality control program to monitor microbiological stains and staining techniques....
... KWIK-QC Slides have a positive and negative ... inoculation. With these slides, perform QC and ... enhance their education and training programs by ... interpretation, all on one slide! KWIK-QC slides ...
Microbiology QC Slides come with one or two droplets of an air-dried and methanol-fixed microorganism, or a single smear containing a designated microorganism population....
... Well Plate Capability The Equalizer 384 ... Equalizerexpandable and equal tip spacing, choice of two ... In addition, this model allows you to evenly ... and accessing many gels and for use with ...
Medicine Products: